Implantable cardioverter–defibrillators (ICDs) are lifesaving and are placed based
on guideline recommendations for primary or secondary prevention of fatal arrhythmic
death due to underlying cardiomyopathic processes.
1
Although the benefits of ICD therapy are clear, potential drawbacks such as inappropriate
shocks can lead to significant morbidity and may be associated with increased mortality.
- Al-Khatib S.M.
- Stevenson W.G.
- Ackerman M.J.
- et al.
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias
and the prevention of sudden cardiac death: executive summary: a report of the American
College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
and the Heart Rhythm Society.
Heart Rhythm. 2018; 15: e190-e252
2
Indwelling leads and devices are prone to bloodstream infections.
3
Psychosocial aspects, such as posttraumatic stress disorder from shocks,
4
and disqualification or restrictions in certain vocations, driving, and competitive
sports can be devastating to the psyche of patients.
5
Thus, shared decision-making between the patient and physician should be established
before any ICD insertion.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart Rhythm. 2018; 15: e190-e252
- Reduction in inappropriate therapy and mortality through ICD programming.N Engl J Med. 2012; 367: 2275-2283
- Management of bacteremia in patients living with cardiovascular implantable electronic devices.Heart Rhythm. 2016; 13: 2247-2252
- Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease.Int J Cardiol. 2013; 168: 3779-3784
- Sports and driving with an implantable cardioverter-defibrillator.Cardiol Rev. 2017; 25: 36-42
- Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction.J Card Fail. 2013; 19: 426-430
- Estimating the risks and benefits of implantable cardioverter defibrillator generator replacement: a systematic review.Pacing Clin Electrophysiol. 2016; 39: 709-722
- Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry.Heart Rhythm. 2019; 16: 733-740
- Defibrillator implantation in patients with nonischemic systolic heart failure.N Engl J Med. 2016; 375: 1221-1230
- Predictors and outcomes of cardiac resynchronization therapy extended to the second generator.Heart Rhythm. 2017; 14: 1793-1800
- Risk of appropriate therapy and death before therapy after implantable cardioverter-defibrillator generator replacement.Circ Arrhythm Electrophysiol. 2018; 11: e006155
Article info
Publication history
Published online: November 23, 2018
Footnotes
The authors report no conflict of interests to disclose in relationship to the contents of the article.
Identification
Copyright
© 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
